Clinical Trial Update: Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy [Phase 4]

View source ↗

Summary

A Phase 4 study of ranolazine (Ranexa) in patients with coronary artery disease and painful polyneuropathy was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Polyneuropathy

Drugs mentioned

• Ranexa (ranolazine)

Snippet

Sponsor: Gilead Sciences | Conditions: Coronary Artery Disease, Pain | Phase 4 | Status: TERMINATED | Results posted: 2014-06-30